|Bid||173.28 x N/A|
|Ask||174.80 x N/A|
|Day's Range||172.28 - 174.78|
|52 Week Range||113.36 - 230.45|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 26, 2023 - May 01, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for DUL.BE
Healthcare growth stocks are often sought out by investors looking for market disruptors. That’s because these stocks can potentially deliver high revenue growth, earnings, and stock price. As an evolving sector, the healthcare industry is seeing high demand for innovative solutions to high patient costs and technology-driven efficiency. Examples of healthcare growth stocks include pharmaceutical companies developing new drugs, medical device manufacturers creating innovative devices, and health
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies for patients in international markets, have announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary, Slovakia, Lithuania, Estonia and Latvia, in addition to Israel.
CAMBRIDGE, Mass., March 08, 2023--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) the leading RNAi therapeutics company, announced today the appointment of Peter Kellogg to its Board of Directors. Mr. Kellogg is an accomplished industry executive with extensive global financial and strategic management experience.